Trial Profile

A Randomized-Withdrawal, Double-Masked, Placebo-Controlled Study of the Efficacy and Safety of Gevokizumab in Treating Subjects With Behcet's Disease Uveitis

Status: Discontinued

Phase of Trial: Phase III

Latest Information Update: 24 Oct 2015

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Gevokizumab (Primary)
Indications Behcet's syndrome; Uveitis
Focus Registrational; Therapeutic Use
Acronyms EYEGUARD™-US
Sponsors XOMA

Most Recent Events

15 Oct 2015 Planned primary completion date changed from 1 Sep 2015 to 1 Oct 2015 as per ClinicalTrials.gov.record.
15 Oct 2015 Status changed from recruiting to discontinued as per ClinicalTrials.gov.record.
04 Nov 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com